ASH 2023 | Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, highlights the crucial role of optimal therapy sequencing for maximizing survival and minimizing toxicities in transplant-ineligible patients with multiple myeloma (MM). An analysis of real-world evidence revealed that with strategic sequencing, transplant-ineligible patients can achieve a 10-year survival. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Janssen, Binding Site, Millenium, BMS (Celgene), Sanofi, Regeneron, Pharmacyclics, Pfizer, Merck, Kite, Juno, Bayer, Aztrazeneca, AMGEN, Adaptive Biotechnologies, AbbVie
Membership on Board of Directors/Advisory Committee: AZBio, Antegene, Oncotracker, Caris Life Sciences, Adaptive Biotechnologies
Patents & Royalties: FISH
